Urokinase (1 brand name, 1 dosage form, 1 route)
Available dosage forms: INJECTABLE.
Routes of administration: INJECTION.
Brand Names
- KINLYTIC
Indications and Usage
Kinlytic™ is indicated in adults:For the lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments.For the lysis of pulmonary emboli accompanied by unstable hemodynamics, i.e., failure to maintain blood pressure without supportive measures.The diagnosis should be confirmed by objective means, such as pulmonary angiography or non-invasive procedures such as lung scanning.
Dosage and Administration
Kinlytic™ IS INTENDED FOR INTRAVENOUS INFUSION ONLY.Kinlytic™ treatment should be instituted soon after onset of pulmonary embolism. Delay in instituting therapy may decrease the potential for optimal efficacy (see CLINICAL PHARMACOLOGY).
Contraindications
The use of Kinlytic™ is contraindicated in patients with a history of hypersensitivity to the product (see WARNINGS and ADVERSE REACTIONS). Because thrombolytic therapy increases the risk of bleeding, Kinlytic™ is contraindicated in the situations listed below (see WARNINGS).Active internal bleedingRecent (e.g., within two months) cerebrovascular accidentRecent (e.g., within two months) intracranial or intraspinal surgeryRecent trauma including cardiopulmonary resuscitationIntracranial neoplasm, arteriovenous malformation, or aneurysmKnown bleeding diathesesSevere uncontrolled arterial hypertension
Adverse Reactions
The most serious adverse reactions reported with Kinlytic™ administration include fatal hemorrhage and anaphylaxis (see WARNINGS).
Drug Interactions
Anticoagulants and agents that alter platelet function (such as aspirin, other non-steroidal anti-inflammatory agents, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of serious bleeding.Administration of Kinlytic™ prior to, during, or after thrombolytic agents may increase the risk of serious bleeding.Because concomitant use of Kinlytic™ with agents that alter coagulation, inhibit platelet function, or are thrombolytic may further increase the potential for bleeding complications, careful monitoring for bleeding is recommended.The interaction of Kinlytic™ with other drugs has not been studied and is not known.